Wang Yixuan, Sun Jie, Li Nan, Che Shuanlong, Jin Tiefeng, Liu Shuangping, Lin Zhenhua
Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Yanbian University, Yanji, 133002, Jilin, China.
Department of Pathology & Cancer Research Center, Yanbian University Medical College, Yanji, 133002, Jilin, China.
J Ovarian Res. 2017 Apr 7;10(1):26. doi: 10.1186/s13048-017-0322-7.
Accumulated evidence has demonstrated that Mammalian hepatitis B X-interacting protein (HBXIP) has broad roles in cancer. Although HBXIP is associated with a variety of cancers, the HBXIP protein expression level and its clinical significance in ovarian cancer have not yet been determined. The aim of this study is to investigate the association between HBXIP expression and the clinicopathological features of ovarian cancer patients to determine whether HBXIP may be correlated with a poor prognosis in ovarian cancer patients.
HBXIP protein expression was assessed in a well-characterized series of ovarian cancer tissue samples (n = 120) with long-term follow-up, using immunohistochemistry to determine the location pattern and expression of HBXIP in ovarian cancer. The localization of HBXIP was detected in SKOV-3 ovarian cancer cells using immunofluorescence (IF) staining. The relationship between high HBXIP expression and the clinicopathological features of ovarian cancer patients was analyzed by Chi-square and Fisher's exact test. Overall survival (OS) rates of all the ovarian cancer patients were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazards regression model.
IF staining revealed strongly positive signals for HBXIP in both cytoplasm and nucleus, but mainly in the cytoplasm of SKOV-3 ovarian cancer cells. High HBXIP expression was predominantly observed in ovarian cancer tissues but not the adjacent non-tumor ovarian tissues. The strongly positive rate of HBXIP expression was 60.0% (72/120) in ovarian cancer and was significantly higher than in adjacent non-tumor tissues (17.4%, 4/23) (P = 0.000). High HBXIP expression was positively correlated with the occurrence of lymph node metastases (P = 0.025), histological grade (P = 0.036) and clinical stage (P = 0.003). The patients with high HBXIP expression had lower overall survival (OS) rates. Moreover, multivariate analysis indicated that HBXIP, in addition to the clinical stage, was a significant independent prognostic factor in patients with ovarian cancer.
High-level expression of HBXIP is associated with the progression of ovarian cancer and may be an effective biomarker for poor prognostic evaluation as well as a potential molecular therapy target for ovarian cancer patients.
越来越多的证据表明，哺乳动物乙型肝炎X相互作用蛋白（HBXIP）在癌症中具有广泛作用。尽管HBXIP与多种癌症相关，但HBXIP蛋白在卵巢癌中的表达水平及其临床意义尚未确定。本研究旨在探讨HBXIP表达与卵巢癌患者临床病理特征之间的关系，以确定HBXIP是否可能与卵巢癌患者的不良预后相关。
在一系列经过充分表征且长期随访的卵巢癌组织样本（n = 120）中评估HBXIP蛋白表达，采用免疫组织化学方法确定HBXIP在卵巢癌中的定位模式和表达。使用免疫荧光（IF）染色在SKOV-3卵巢癌细胞中检测HBXIP的定位。采用卡方检验和Fisher精确检验分析高HBXIP表达与卵巢癌患者临床病理特征之间的关系。使用Kaplan-Meier方法计算所有卵巢癌患者的总生存率（OS），并使用Cox比例风险回归模型进行单因素和多因素分析。
IF染色显示HBXIP在细胞质和细胞核中均呈强阳性信号，但主要在SKOV-3卵巢癌细胞的细胞质中。高HBXIP表达主要在卵巢癌组织中观察到，而在相邻的非肿瘤性卵巢组织中未观察到。HBXIP表达的强阳性率在卵巢癌中为60.0%（72/120），显著高于相邻的非肿瘤组织（17.4%，4/23）（P = 0.000）。高HBXIP表达与淋巴结转移的发生（P = 0.025）、组织学分级（P = 0.036）和临床分期（P = 0.003）呈正相关。高HBXIP表达的患者总生存率较低。此外，多因素分析表明，除临床分期外，HBXIP是卵巢癌患者的一个重要独立预后因素。
HBXIP的高水平表达与卵巢癌的进展相关，可能是不良预后评估的有效生物标志物，也是卵巢癌患者潜在的分子治疗靶点。
